Mucolipidosis II/III Enzyme Panel (Plasma)

Test Information

Elevated activity of lysosomal hydrolases in plasma is consistent with a diagnosis of mucolipidosis type II/III.

Turnaround Time

10 days

CPT Code(s)

82657 x2

Cost

$400


Enzymes

Alpha-fucosidase
Beta-glucuronidase
Hexosaminidase

Clinical Information

Mucolipidosis II (ML II), also known as I-Cell disease, and Mucolipidosis IIIA (ML IIIA), also known as Pseudo-Hurler Polydystrophy, are lysosomal storage disorders caused by a deficiency of N-acetylglucosamine-1-phosphotransferase (NAPT). ML II is associated with a more severe course including growth failure and failure to thrive, severe developmental delay, coarse facial features, skeletal anomalies and frequent upper respiratory infections. ML II is often lethal in childhood. ML IIIA is associated with a similar, but milder course with a wider spectrum of features and severity. In ML II and ML IIIA, lysosomal hydrolase enzymes are not properly targeted to the lysosome. Therefore, the enzyme activity of multiple lysosomal hydrolases is increased in plasma and other body fluids.

Methodology

The activity of 3 lysosomal hydrolases are measured from plasma The assay uses 4-methylumbelliferyl substrates to measure the activities of acid alpha-fucosidase, beta-glucuronidase, hexosaminidase. Prenatal diagnosis and carrier testing via enzyme analysis are not available.

Specimen Requirements

Enzyme activity is measured in plasma. Please send 5-7 ml of whole blood in a green top (sodium heparin) tube, or spin down a whole blood sample, pull off the plasma, and freeze.

Transport Instructions

Whole blood samples should be shipped at ambient temperature and must arrive at the laboratory the next day. If plasma has been separated and frozen, send frozen via overnight shipping, preferably on dry ice.

Have Questions? Need Support?

Call our laboratory at 1-800-473-9411 or contact one of our Laboratory Genetic Counselors for assistance.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC

Meet Ella

We will remember February 26th for the rest of our lives. On that day, we received the call from the Greenwood Genetic Center that they had discovered our daughter, Ella Marie, has Kleefstra syndrome. Very early on, my wife, Kelly, observed Ella being delayed in some of her milestones. Kelly monitored Ella’s progression and sought out testing in an effort to get Ella some assistance. Along the way, we were sent to GGC and met with LEARN MORE

In The News